Skip to content

Serial, integrated, non-invasive mapping of electro-mechanical activation of the human heart under various pacing conditions.

Serial, integrated, non-invasive mapping of electro-mechanical activation of the human heart under various pacing conditions. - Non-invasive mapping of cardiac electro-mechanical activation patterns.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON40063
Enrollment
150
Registered
2011-11-11
Start date
2011-12-08
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure heart rhythm disorder

Interventions

None listed

Sponsors

HagaZiekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Humans of at least 18 years old Cardiac conduction disorder for which implantation of pacemaker is indicated Rhythm disorders for which electrophysiological examination is performed.

Exclusion criteria

Exclusion criteria: Humans younger than 18 years old. Individuals not capable of providing informed consent. Women of child bearing age and not on reliable birth control program/pregnant women.

Design outcomes

Primary

MeasureTime frame
The altered pathway of electrical and mechanical activation of the human heart and the accompanying hemodynamic response. Electrical activation: Electrical activation patterns of the human heart. Periods of conduction (pq-time, qrs-duration, qtc-time). Mechanical activation: Left ventricle (LV) contraction pattern. LV ejection fraction, stroke volume, end-diastolic pressure and volume of left ventricle. Hemodynamics of patient during study. Quality of life during study. Cardiac Electrical activation times registered simultaneously during EPS in patients suffering from arrhythmias and in individuals in whom structural heart disease is ruled out. Atrial scar in patients after ablation therapy.

Secondary

MeasureTime frame
(serious) adverse events

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)